United Therapeutics investor relations material
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company markets vasopressin receptor antagonists; Atrasentan, an endothelin receptor antagonist; Leflunomide, an immunomodulator; Pazopanib, a vascular endothelial growth factor inhibitor for the treatment of advanced renal cell carcinoma; Aranesp and Nplate for anemia; and Votrient for hepatocellular carcinoma. It also develops Auristatin peptide analog therapeutics as anticancer agents. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.
Ticker
UTHRCountry
US